Tivantinib in Treating Patients With Metastatic Prostate Cancer

Summary

This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2012-01-11

Primary completion

2015-08-18

Completion

2015-08-18

Outcome

Met primary endpoint

registry Arm I (Tivantinib) vs Arm II (Placebo); p = 0.02; Log Rank NCT01519414 ↗

Drugs

Indications